E197
E197 is the inhibitor for DOCK5 that destroys the podosome belt structure of osteoclasts, thereby inhibiting the bone resorption (IC50=3.44 μM in human osteoclast) . E197 inhibits the Rac in DOCK5 expressing HEK293 cell with an IC50 of 36 μM. E197 prevents the bone loss in mouse ovariectomized models[1].
Product Specifications
CAS Number
[2378515-04-7]
UNSPSC
12352005
Target
DOCK
Related Pathways
Immunology/Inflammation
Field of Research
Metabolic Disease
Smiles
O=S1([C@]2(CN(CC2)CC3=CC=C(C=C3)Cl)[C@H](CN1C4=CC=CC=C4)O)=O
Molecular Formula
C19H21ClN2O3S
Molecular Weight
392.90
References & Citations
[1]Mounier L, et al., Novel 2,7-Diazaspiro[4,4]nonane Derivatives to Inhibit Mouse and Human Osteoclast Activities and Prevent Bone Loss in Ovariectomized Mice without Affecting Bone Formation. J Med Chem. 2020 Nov 25;63 (22) :13680-13694.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6003824-01 0.1 mg
UBCH9 (Ubiquitin-conjugating Enzyme E2 E3, Ubiquitin-protein Ligase E3, Ubiquitin Carrier Protein E3, Ubiquitin-conjugating Enzyme E2-23kD, UbcH9, UBE2E3, UBCE4)
Ask
View Details 
MBS6003824-02 5x 0.1 mg
UBCH9 (Ubiquitin-conjugating Enzyme E2 E3, Ubiquitin-protein Ligase E3, Ubiquitin Carrier Protein E3, Ubiquitin-conjugating Enzyme E2-23kD, UbcH9, UBE2E3, UBCE4)
Ask
View Details